Entries |
Document | Title | Date |
20100273701 | USE OF SALUSIN BETA ALONE OR IN COMBINATION WITH OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 10-28-2010 |
20100286026 | NOVEL PROTEIN - Provided is a novel, isolated polypeptide including an amino acid sequence of SEQ. ID. NO: 2 or SEQ. ID. NO: 4, and the nucleic acid molecule which encodes it. The polypeptide may be used in a method for treating various diseases including cancer, immune associated, viral and inflammatory diseases. | 11-11-2010 |
20100311645 | PROTEINS FROM THE WEBS OF NEPHILENGYS CRUENTATA, AVICULARIA JURUENSIS AND PARAWIXIA BISTRIATA SPIDERS ISOLATED FROM BRAZILIAN BIODIVERSITY - The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of | 12-09-2010 |
20100331239 | CD14 AND PEPTIDES THEREOF FOR PROTECTION OF CELLS AGAINST CELL DEATH - Provided is a method of using soluble CD14 or peptides derived therefrom for protecting cells from death, specifically from apoptotic cell death. Further provided are compositions including CD14 or CD14 peptides and methods for protecting cells, in particular lymphocytes, from apoptotic cell death. The compositions and methods are relevant, in particular, for the treatment of various immune deficiencies associated, for example, with cell transplantation procedures, autoimmune diseases and infectious diseases such as HIV. | 12-30-2010 |
20110034370 | BIS-MET HISTONES - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 02-10-2011 |
20110039760 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. | 02-17-2011 |
20110053832 | NATURAL ANTIMICROBIAL COMPOSITION - Natural antimicrobials for foods, such as salad dressings and dairy products to target a broad spectrum of food emulsion spoilage microorganisms such as lactic acid bacteria and fungi such as general yeast and even acid-tolerant yeast (such as | 03-03-2011 |
20110053833 | SYNTHETIC PEPTIDES AND THEIR USE - At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 03-03-2011 |
20110077192 | Novel Antibacterial Peptides - The present invention relates to monomeric and multimeric peptidic compounds which have antimicrobial activity, particularly against Gram-positive and Gram-negative bacteria. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, for use as a disinfectant and/or detergent or for use as a preservative. | 03-31-2011 |
20110105383 | METHODS AND COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR polypeptide or peptide or fragment or derivative or analog thereof to the individual. | 05-05-2011 |
20110105384 | USE OF POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY - The present invention relates to the use of polypeptides related to a | 05-05-2011 |
20110136726 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 06-09-2011 |
20110143996 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE - The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo core and that can be a CXC, CC, or C class chemokine Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods. | 06-16-2011 |
20110160122 | Polypeptides having Antimicrobial Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 06-30-2011 |
20110190197 | PLANT DERIVED ANTIBIOTIC PEPTIDE RICH IN GLYCINE - The present invention relates to a novel peptide extracted from guava ( | 08-04-2011 |
20110201545 | GEL BASED LIVESTOCK FEED, METHOD OF MANUFACTURE AND USE - A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component is solubilized or the sequestrates affecting the reactivity between the alginate and the calcium component is removed such that a gel feed is formed that includes a gel matrix containing the feed nutrient components. The gel feed may then be fed to the livestock. In another aspect of the present invention, piglets are weaned by feeding the gel feed for at least seven days directly after weaning. The gel feed may also include protein derived from blood with or without egg protein. | 08-18-2011 |
20110207656 | MUC1, CASPASE-8, and DED-CONTAINING PROTEINS - The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of, e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease. | 08-25-2011 |
20110212885 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING PEPTIDES AS PRESERVATIVE - A method and a contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight. | 09-01-2011 |
20110218138 | Pharmaceutical composition containing polypeptide fragments of serralysins - The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors. | 09-08-2011 |
20110237499 | HYBRID TRIPYRROLE-OCTAARGININE COMPOUNDS AND THEIR USE AS MEDICAMENT IN THE TREATMENT OF CANCER AND MICROBIAL ILLNESSES - Hybrid tripyrrole-octaarginine compounds. Hybrids formed by a tripyrrole group bound to a polyarginine peptide which permit the efficient cellular internalization and promote a greater affinity for the DNA. The method of obtainment and uses thereof. | 09-29-2011 |
20110237500 | CECROPIN-MAGAININ HYBRID PEPTIDES - The present invention relates to a biocidal fusion peptide of SEQ ID NO: 1 or a sequence with at least 90% identity thereto, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide, and use of the peptide in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection. | 09-29-2011 |
20110245148 | ACETIC ACID AND A BUFFER - The present invention relates to a composition comprising: a) 0.01-20% wt/wt acetic acid and b) a physiologically tolerable buffer capable of maintaining acetic acid at a pH in the range of 2-7; and use of such a composition as an antimicrobial agent. | 10-06-2011 |
20110245149 | METHODS TO PREVENT AND TREAT DISEASES - This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue. | 10-06-2011 |
20110269669 | SELF-DECONTAMINATING COATINGS CONTAINING ANTIMICROBIAL PEPTIDES - Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from | 11-03-2011 |
20110288006 | Peptides and methods for inducing cell death - The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease. | 11-24-2011 |
20110301076 | ANTIMICROBIAL COMPOUNDS - The present invention relates to a compound of formula (I) AA-AA-AA-R | 12-08-2011 |
20110319319 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE - The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γ | 12-29-2011 |
20120004159 | POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 01-05-2012 |
20120015869 | ANTIMICROBIAL AQUEOUS SOLUTION AND ITS PREPARATION METHOD - The antimicrobial aqueous solution of the present invention comprises an original undiluted aqueous solution containing: 25 μg/ml to 50 μg/ml of an amphipathic preservative comprising a monoglycerol monolaurate; and 12.5 μg/ml to 30 μg/ml of an ε-polylysine. In preparing the antimicrobial aqueous solution, dissolution of the amphipathic antimicrobial can be promoted by addition of a sucrose monolaurate and by heating to 35° C. to 60° C. This antimicrobial aqueous solution can be used effectively, even within a range of concentrations lower than concentrations to be typically used for amphipathic antimicrobials. It is possible to adopt a diglycerol monolaurate, instead of the monoglycerol monolaurate. | 01-19-2012 |
20120028882 | METHOD FOR REMOVING ENDOTOXIN FROM PROTEINS - Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing. | 02-02-2012 |
20120046220 | PHOSPHOLIPID DEPOT - The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same. | 02-23-2012 |
20120065125 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 03-15-2012 |
20120083439 | Method of Preparing Water-Soluble and Biodegradable Antimicrobial Agent - A method of preparing a water-soluble and biodegradable antimicrobial agent is provided. The method includes treating a polypeptide compound with sodium hypochlorite for at least 1 min, such that the polypeptide compound has at least one N-halamine group and has good antimicrobial effect. By using the method of the present invention, a chemical synthesis process is not required and an organic solvent is not required either, and thus, an antimicrobial agent having high water solubility, biodegradability, non-toxicity, good sterilization effect, and regeneration can be prepared with reduced harms to the environment. | 04-05-2012 |
20120083440 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 04-05-2012 |
20120108496 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST - The present invention provides novel short-chain peptides, which primarily act as parathyroid hormone (PTH/PTH-1) receptor agonist. These short-chain peptides exhibit increased stability to proteolytic cleavage. Most of short-chain peptides were found to be stable in rat plasma up to 24 hours (in vitro), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, some of the short-chain peptides can also be delivered by oral routes of administration, for the treatment/prevention of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair. A-Z | 05-03-2012 |
20120108497 | COMPOSITIONS FOR CONFERRING TOLERANCE TO VIRAL DISEASE IN SOCIAL INSECTS, AND THE USE THEREOF - Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed. | 05-03-2012 |
20120129761 | PREPARATION OF BONE CEMENT COMPOSITIONS - A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising
| 05-24-2012 |
20120157372 | HUMAN MILK PEPTIDES - The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations. | 06-21-2012 |
20120157373 | ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS - Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents. | 06-21-2012 |
20120214731 | COMPOUND WS 727713 - The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to | 08-23-2012 |
20120220518 | THERAPEUTIC AGENT DELIVERY SYSTEM AND METHOD - A therapeutic agent delivery system includes a therapeutic agent delivery platform and a therapeutic guest agent. The therapeutic agent delivery platform is capable of being implanted in a tissue being treated. The platform includes a substrate and at least one host molecule coupled to the substrate. The therapeutic guest agent is capable of reversibly coupling with the host molecule when administered to the tissue being treated. The reversible coupling is defined by the binding affinity between the host molecule and the therapeutic guest agent. The therapeutic guest agent is delivered at a rate determined by the affinity release rate between the host molecule and the therapeutic guest agent. The degradation rate of the therapeutic guest agent may be slower than the affinity release rate between the host molecule and the therapeutic guest agent. | 08-30-2012 |
20120231995 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 09-13-2012 |
20120258906 | USE OF PEPTIDES AS ANTIDANDRUFF AGENTS - The present invention relates to compositions comprising peptides with antidandruff activity. The invention also relates to the use of these peptides as antidandruff agents, or in methodes for treating dandruff. | 10-11-2012 |
20120270772 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 10-25-2012 |
20120283171 | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified bovine somatotropin polypeptides and uses thereof are provided. | 11-08-2012 |
20120283172 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified porcine somatotropin polypeptides and uses thereof are provided. | 11-08-2012 |
20120289454 | METALLODRUGS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES, AND METHODS OF MANUFACTURE AND USE THEREOF - It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target. | 11-15-2012 |
20120309676 | Lantibiotic Salts - Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant | 12-06-2012 |
20120316102 | ANTIMICROBIAL PEPTIDES OF THE CECROPIN FAMILY AND THERAPEUTIC USES THEREOF - The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections. | 12-13-2012 |
20130029900 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF - The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 01-31-2013 |
20130029901 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 01-31-2013 |
20130035283 | ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT - The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis. | 02-07-2013 |
20130059772 | Use of Repeat Sequence Protein Polymers in Personal Care Compositions - The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein polymer having bioactivity. | 03-07-2013 |
20130065818 | Arylamide Compounds And Compositions And Uses Thereof - The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals. | 03-14-2013 |
20130072422 | COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 03-21-2013 |
20130116167 | ANTI-MART-1 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR. | 05-09-2013 |
20130150284 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 06-13-2013 |
20130157930 | LINEAR POLYESTERAMIDES FROM AMINOPHENOLIC ESTERS - The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by | 06-20-2013 |
20130165368 | ANTIMICROBIAL COMPOUNDS - A composition for use in the prevention and/or treatment of microbial infection comprising essentially of one or more pure alkanol alkoxylates, diol alkoxylates and/or triol alkoxylates. | 06-27-2013 |
20130172235 | ORAL TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 07-04-2013 |
20130172236 | METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same. | 07-04-2013 |
20130210705 | METALLODRUGS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES AND METHODS OF MANUFACTURE AND USE THEREOF - It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms. | 08-15-2013 |
20130210706 | DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L | 08-15-2013 |
20130217618 | NUCLEIC AND AMINO ACID SEQUENCES FOR THE CONTROL OF PATHOGEN AGENTS - The present invention reveals a nucleic acid sequence from | 08-22-2013 |
20130225481 | ANTIMICROBIAL PEPTIDES - The present invention relates to antimicrobial peptides, to their use as antimicrobial agents and to their use in the treatment of (infectious) diseases, in particular infectious diseases caused by Gram-positive bacteria, Gram-negative bacteria, yeast or fungi. The present invention further relates to pharmaceutical compositions and kits comprising the antimicrobial peptides and to a method of lysing bacterial, yeast or fungal cells. The antimicrobial peptides consist of one of the following general formula: Wherein X is a hydrophobic amino acid, Y is a cationic amino acid, Z is an amino acid having a free thiol or thioether group, n is 2-4 and m is 0 or 1. | 08-29-2013 |
20130281359 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS - A compound of formula (I): | 10-24-2013 |
20130288951 | COMPOSITIONS AND METHODS FOR COATING IMPLANT SURFACES TO INHIBIT SURGICAL INFECTIONS - Infection-inhibiting compositions suitable for coating surfaces of implantable medical implants, including compositions and devices for coating medical devices in the operating room prior to implantation in a patient. Methods for inhibiting infection at the site of implantation of an orthopedic device in a human or animal subject, comprise rubbing a surface of the device, prior to implantation, with an infection-inhibiting composition having a waxy matrix comprising an infection-inhibiting material selected from the group consisting of a lipid, an antimicrobial agent, and mixtures thereof, wherein a thin layer of the infection-inhibiting material is deposited on the surface of the device. Medical implants which may be treated in the methods of this technology include orthopedic implants. Lipids include long-chain diacylglycerides or triacylglycerides, which may be saturated or unsaturated, such as lecithin or a purified form of phosphatidylcholine. | 10-31-2013 |
20130303437 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS - The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the | 11-14-2013 |
20130345118 | MATRIX SCAFFOLD WITH ANTIMICROBIAL ACTIVITY - The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides. | 12-26-2013 |
20140051625 | Bone Targeted Therapeutics and Methods of Making and Using the Same - The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones. | 02-20-2014 |
20140066362 | METHOD FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES - The invention provides materials and methods for treating infections by reducing endogenous microbial H | 03-06-2014 |
20140142025 | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent - The disclosure describes collagen constructs comprising antimicrobial agents and related methods. | 05-22-2014 |
20140142026 | Anti-Pathogen Treatments - Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain, and their methods of use in preventing or treating a pathogen infection in a cell or organism are described. The pathogen-detection domain and effector domain of the chimeric molecules are domains not typically found in nature to be associated together. Agents are also described herein having at least one pathogen-interacting molecular structure and at least one effector-mediating molecular structure, the agent being one that is non-naturally-occurring in a cell. The methods of prevention and treatment described herein are effective for a broad spectrum of pathogens and exhibit little or no toxic side-effects. Assays for the detection of a pathogen, pathogen component, or product produced or induced by a pathogen, are also provided. | 05-22-2014 |
20140142027 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient. | 05-22-2014 |
20140155317 | SELECTIVELY TARGETED ANTIMICROBIAL PEPTIDES AND THE USE THEREOF - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 06-05-2014 |
20140179593 | METHODS AND COMPOSITIONS FOR INHIBITING NEDDYLATION OF PROTEINS - Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl). | 06-26-2014 |
20140235530 | Spray Drying Vancomycin - A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%), ethanol (0-10%), and a citrate buffer. Spray dried vancomycin has favorable reconstitution times and water content. | 08-21-2014 |
20140249073 | BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 09-04-2014 |
20140256612 | ANTIBIOTIC CONJUGATES DIRECTLY LINKED WITH STEROID DRUGS - The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug. | 09-11-2014 |
20140256613 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed. | 09-11-2014 |
20140274875 | Hemostatic Compositions And Methods - Compositions and methods for achieving hemostasis. Hemostatic compositions comprise a phospholipid, and optionally, an anti-infective agent. The hemostatic composition can be administered to a bleeding bone to achieve hemostasis. | 09-18-2014 |
20140287987 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 09-25-2014 |
20140303069 | Anti-Microbial Peptides and Methods of Use Thereof - Anti-microbial peptides and methods of use are provided. | 10-09-2014 |
20140309159 | COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS - The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation. | 10-16-2014 |
20140309160 | PLANT DISEASE CONTROL AGENT - The present invention relates to a plant disease control agent containing a compound represented by the following formula (1) or salt thereof as an active ingredient (in the formula, R | 10-16-2014 |
20140349917 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 11-27-2014 |
20150031600 | DESIGNED BIOSURFACTANTS, THEIR MANUFACTURE, PURIFICATION AND USE - The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an α-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins. | 01-29-2015 |
20150031601 | Antimicrobial Peptide Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 01-29-2015 |
20150038406 | PHARMACEUTICAL FORMULATIONS OF TRANEXAMIC ACID AND THEIR USE - The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration. | 02-05-2015 |
20150080290 | COMPOSITIONS AND USES OF ANTIMICROBIAL MATERIALS WITH TISSUE-COMPATIBLE PROPERTIES - Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken. | 03-19-2015 |
20150094255 | Lectin Conjugates for Mucin Hydration - The invention provides, inter alia, conjugates of a hydratable polymer (such as PEG, polyethylene glycol) and a lectin (such as wheat germ agglutinin, WGA), compositions comprising these conjugates, as well as methods and targeted uses of these conjugates and compositions for, e.g., lubricating, maintaining hydration of rehydrating, and/or inhibiting microorganism colonization of a biological surface in need thereof. | 04-02-2015 |
20150094256 | USE OF THE CATHELICIDIN LL-37 AND DERIVATIVES THEREOF FOR WOUND HEALING - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37. | 04-02-2015 |
20150141323 | PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USE - The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof. | 05-21-2015 |
20150148285 | SALT AND PROTEASE-RESISTANCE OF ANTIMICROBIAL PEPTIDE AND THE MANUFACTURE THEREOF - The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously. | 05-28-2015 |
20150306173 | PHOSPHOLIPID DEPOT - The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same. | 10-29-2015 |
20150313960 | NOVEL DEPSIPEPTIDE AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 11-05-2015 |
20150328283 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents, which include a plurality of positively charged amino acid residues and at least one omega-amino-fatty acid residue linking therebetween, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 11-19-2015 |
20150329607 | MUTANT NGAL PROTEINS AND USES THEREOF - In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract. | 11-19-2015 |
20150343014 | TOPICAL ANTIMICROBIAL DERMATOLOGICAL COMPOSITION - The invention relates to a composition that may be used in dermatology. | 12-03-2015 |
20150359844 | ANTIMICROBIAL BACTERIA STRAINS AND USES THEREOF - The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents. | 12-17-2015 |
20150366193 | COMPOSITION WITH HIGH ANTIMICROBIAL ACTIVITY AND LOW TOXICITY - Improved synthetic copolypeptide antimicrobials contain cationic amino acid residues and may be based on a blocky sequence. These antimicrobials show low mammalian toxicity and may undergo directed self-assembly. The inventive synthetic copolypeptides are useful in treatment of wounds and other infections. | 12-24-2015 |
20160000079 | Novel small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating - Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment. | 01-07-2016 |
20160000924 | METHODS FOR PRODUCING A BIODEGRADABLE CHITOSAN COMPOSITIONS AND USES THEREOF - The invention provides improved methods for generating biodegradable chitosan compositions, and therapeutic methods of using such compositions to deliver therapeutic agents. | 01-07-2016 |
20160038631 | Acrylic Cements for Bone Augmentation - The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component. | 02-11-2016 |
20160060298 | BETA-HAIRPIN PEPTIDOMIMETICS - Beta-hairpin peptidomimetics of the general formula (I), cyclo(P | 03-03-2016 |
20160082114 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 03-24-2016 |
20160090571 | CULTURE MEDIA AND METHODS FOR CULTURING MICROORGANISMS - Methods and culture media for culturing a microorganism associated with Morgellons disease are provided. In exemplary embodiments, methods are provided that may include adding a microorganism associated with Morgellons disease to a solution containing ferrous iron, sugar and water or to a solid growth medium containing agar and ferrous iron. Also provided are compositions containing a microorganism associated with Morgellons disease as well as methods for isolating lipids and proteins from this microorganism and methods for inhibiting its growth. | 03-31-2016 |
20160114002 | COMPOSITIONS COMPRISING PLANT PROTEINS AND METHODS FOR PREVENTION OF METABOLIC AND CARDIOVASCULAR PATHOLOGIES IN PATIENT WITH CARDIOMETABOLIC RISK, INCLUDING HYPERGLYCEMIA - A composition for oral administration in humans comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture thereof, and:
| 04-28-2016 |
20160137599 | 2-METHYLTHIOPYRROLIDINES AND THEIR USE FOR MODULATING BACTERIAL QUORUM SENSING - Compounds of Formula (I) are disclosed herein and their use in inhibiting quorum sensing in bacteria. | 05-19-2016 |
20160184448 | CROSS-LINKED COLLAGEN WITH AT LEAST ONE BOUND ANTIMICROBIAL AGENT FOR IN VIVO RELEASE OF THE AGENT - The disclosure describes collagen constructs comprising antimicrobial agents and related methods. | 06-30-2016 |
20160199447 | LIPID NANOPARTICLES FOR WOUND HEALING | 07-14-2016 |
20160200770 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | 07-14-2016 |
20160376738 | ELECTROPROCESSED BIOFUNCTIONAL COMPOSITION - Described are methods for preparing an electroprocessed composition functionalized with bioactive materials and the use of the electroprocessed composition, including use as an engineered extracellular microenvironment and its use in forming three-dimensional matrix for biological application. The electroprocessed composition may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed composition. | 12-29-2016 |
20170231228 | SURFACE TREATMENTS | 08-17-2017 |
20120094931 | COMPOSITIONS AND METHODS TO MODULATE PROGRESSION AND ONSET OF INFLAMMATORY BOWEL DISEASE - Embodiments herein illustrate methods and compositions for treating inflammatory bowel disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or modulating progression of an inflammatory bowel disorder in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin. | 04-19-2012 |
20120309693 | Methods to Accelerate Tissue and Wound Healing Rates and Reduce Swelling and Scar Formation - The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor. | 12-06-2012 |
20130079289 | Pharmaceutical Compositions - Forms and formulations of VX-950 and uses thereof. | 03-28-2013 |
20130316960 | Novel Peptides For Treating and Preventing Immune-Related Disorders, Including Treating And Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 11-28-2013 |
20140296157 | COMPOSITIONS AND METHODS FOR PREPARING A SUBJECT FOR ORGAN OR NON-ORGAN IMPLANTATION - Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery. | 10-02-2014 |
20140309175 | POLYMERIC CONJUGATES OF C1-INHIBITORS - Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via thiol group of the C1 inhibitor is provided. In the polymer conjugates of the present invention, the substantially non-antigenic polymer is attached to either free thiol from a cysteine of thiol generated from disulfide bonds in C1 inhibitor. Alternatively, the substantially non-antigenic polymer is attached to one of more thiols in C1 inhibitor via bifunctional spacer. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided. | 10-16-2014 |
20150057232 | Anti-Inflammatory Composition for Modulating the Cell Response of Neutrophils and Eosinophils - The present invention relates to an anti-inflammatory composition intended for humans and animals for modulating the cell response of the neutrophils and of eosinophils. | 02-26-2015 |
20160008442 | TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY | 01-14-2016 |
20160083430 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS - The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics. | 03-24-2016 |
20160184437 | Polymer, and pharmaceutical composition employing the same - A polymer and a pharmaceutical composition employing the same are disclosed. The polymer includes a first repeating unit, a second repeating unit, and a third repeating unit. In particular, the first repeating unit is | 06-30-2016 |
20160199466 | Methods For Treating Tissue Fibrosis | 07-14-2016 |
20170232081 | METHODS FOR TREATMENT OF AND PROPHYLAXIS AGAINST INFLAMMATORY DISORDERS | 08-17-2017 |